AbbVie Says Rinvoq Holding Up, Humira Erosion Will Continue Into 2024

 
• By Joseph Haas

Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.

Financial Report
AbbVie says Rinvoq is losing some RA market share due to label change

More from Earnings

More from Business